Cannabis for Women's Health Australia — Period Pain, PMDD, Menopause and Pelvic Conditions (2026)

Women’s health conditions have historically been under-researched and under-treated in medicine. Chronic pelvic pain, painful periods, premenstrual mood disorders and menopausal symptoms affect millions of Australian women — and a significant proportion find inadequate relief through conventional treatments. Medicinal cannabis is being explored and increasingly prescribed for these conditions.

Period pain (dysmenorrhoea)

Dysmenorrhoea — painful menstruation — affects approximately 80% of women at some point, with 20% experiencing pain severe enough to limit daily activities. Primary dysmenorrhoea (no identifiable cause) and secondary dysmenorrhoea (caused by conditions including endometriosis and fibroids) both drive the majority of period pain presentations.

Why cannabis helps with period pain:

• Prostaglandin inhibition: Uterine contractions causing period pain are driven by prostaglandin release. CBD has demonstrated prostaglandin inhibitory effects in preclinical models — one of the mechanisms underlying cannabis’s analgesic and anti-inflammatory action
• CB1 receptor analgesia: THC’s direct CB1 receptor analgesic effects reduce the perception of pain centrally — particularly useful for visceral pain (pain originating in internal organs), which is notoriously difficult to treat with conventional NSAIDs
• Muscle relaxation: Myrcene-dominant preparations produce muscle relaxation that directly addresses uterine cramping

Evidence: Clinical evidence specifically for cannabis in dysmenorrhoea is limited — most data is from surveys and observational studies rather than controlled trials. A 2020 Australian survey found that a significant proportion of women using cannabis for period pain reported “a lot” of relief, with few adverse effects. This matches clinical observation by gynaecologists and pain specialists.

For endometriosis: Australia has a dedicated guide to cannabis for endometriosis — a condition that frequently causes severe secondary dysmenorrhoea alongside its other symptoms.

Premenstrual dysphoric disorder (PMDD)

PMDD is a severe form of premenstrual syndrome affecting approximately 3–8% of women of reproductive age. Symptoms in the luteal phase (1–2 weeks before menstruation) include:

• Severe mood swings, irritability, anger
• Depression, hopelessness
• Marked anxiety and tension
• Difficulty concentrating
• Physical symptoms: bloating, breast tenderness, fatigue

PMDD is formally recognised as a depressive disorder by DSM-5. Standard treatments include SSRIs (often dosed cyclically), hormonal contraception and lifestyle modification. A substantial proportion of PMDD patients find incomplete relief.

Cannabis for PMDD:

• CBD’s 5-HT1A serotonin receptor modulation provides anxiolytic and antidepressant effects directly relevant to the mood dysregulation of PMDD
• Balanced CBD:THC preparations help some patients manage the anxiety-irritability component during the luteal phase
• Low-dose THC preparations support sleep during symptomatic periods

Note: PMDD patients who also have anxiety or mood disorders year-round should discuss whether cannabis is appropriate as part of their overall treatment plan — the cyclic nature of PMDD may warrant cyclic cannabis dosing strategies.

Perimenopause and menopause

The menopausal transition (perimenopause typically beginning in the mid-40s) involves significant hormonal fluctuation that produces symptoms affecting sleep, mood, cognition, pain and quality of life.

How cannabis addresses menopausal symptoms:

Vasomotor symptoms (hot flashes, night sweats): Hot flashes are driven by hypothalamic thermoregulatory dysfunction related to oestrogen decline. The endocannabinoid system plays a role in hypothalamic temperature regulation. Preliminary evidence suggests cannabis may reduce hot flash frequency and severity — this is an active area of research. CBD is the most commonly used cannabinoid for this application.

Sleep disturbance: Menopausal sleep disruption is one of the most debilitating symptoms and among the most responsive to cannabis therapy. THC-dominant indica products (myrcene, linalool terpene profile) are highly effective for sleep onset and duration. For women who cannot tolerate THC, CBD alone provides modest sleep improvement.

Mood and anxiety: Perimenopausal anxiety and depression are extremely common and often related to hormonal fluctuation rather than a separate depressive illness. CBD’s anxiolytic and mood-stabilising effects are relevant and well-evidenced. Many Australian GPs now prescribe CBD-dominant products specifically for perimenopausal anxiety.

Musculoskeletal pain: Joint pain and increased musculoskeletal pain are common in perimenopause. Cannabis provides analgesic and anti-inflammatory relief applicable to this presentation.

Cognitive symptoms (“brain fog”): Some menopausal women report improvement in concentration and cognitive clarity with low-dose CBD. Evidence is limited but the CBD neuroprotective mechanisms are plausible contributors.

Genitourinary syndrome of menopause (GSM): Vaginal dryness, irritation and dyspareunia (painful sex) from oestrogen decline are addressed by some women with cannabis-infused topical products. Cannabis topicals applied locally may reduce pain and inflammation without systemic effects. See our cannabis topicals guide for detail on this application.

Chronic pelvic pain

Chronic pelvic pain (CPP) affects approximately 15% of women and is one of the most treatment-resistant pain presentations in medicine. Causes include endometriosis, interstitial cystitis, pelvic floor dysfunction, adenomyosis and idiopathic CPP.

Cannabis is increasingly used in multidisciplinary CPP management:

• THC provides CB1-mediated visceral analgesia — specifically relevant to pelvic/visceral pain
• CBD reduces neuroinflammation and central sensitisation — relevant to CPP where central sensitisation is a significant driver
• Topical preparations may provide localised relief for superficial pelvic pain components

CPP is a well-accepted TGA SAS-B indication. Australian gynaecologists and pain specialists are increasingly incorporating cannabis into CPP management plans.

Interstitial cystitis / bladder pain syndrome

Interstitial cystitis is a chronic bladder condition producing pelvic pain, urinary urgency and frequency. The endocannabinoid system is expressed in bladder tissue. CBD has anti-inflammatory and neurogenic pain effects relevant to bladder inflammation. Some patients use cannabis alongside conventional IC treatments for additional pain and urgency relief.

Fibromyalgia (women are disproportionately affected)

Fibromyalgia affects women at 3–4× the rate of men. See our cannabis for fibromyalgia guide for detailed information. Cannabis is well-evidenced for fibromyalgia and widely prescribed in Australia for this condition.

Hormonal interactions — what women should know

Hormonal contraception: Limited evidence for significant cannabis-contraceptive interactions. Some data suggests cannabis may affect oestrogen metabolism via CYP3A4 enzymes. Discuss with your prescriber if using hormonal contraception — this is unlikely to be clinically significant at therapeutic cannabis doses but is worth noting.

HRT (hormone replacement therapy): No clinically significant interactions identified between cannabis and standard HRT preparations at therapeutic cannabis doses. Women using HRT for menopause management can generally use cannabis concurrently under medical supervision.

Pregnancy and breastfeeding: Cannabis is contraindicated in pregnancy and breastfeeding. THC crosses the placenta and is expressed in breast milk. If you are pregnant, trying to conceive, or breastfeeding, do not use cannabis. Discuss any medicinal cannabis use with your obstetrician.

Accessing medicinal cannabis for women’s health in Australia

All the conditions described above are accepted or approvable TGA SAS-B indications. The telehealth access pathway is available to women across all Australian states and territories:

1. Book a telehealth consultation with a TGA-authorised prescriber
2. Describe your specific symptoms — which part of the cycle is affected, existing treatments tried, symptom severity
3. Receive a tailored prescription — your prescriber will recommend specific products and dosing based on your symptom pattern (cyclic vs constant, daytime vs evening needs)
4. Pharmacy delivery to your door

Australian women’s health specialists and gynaecologists are increasingly familiar with medicinal cannabis prescribing. If your existing GP or gynaecologist is not TGA-authorised, medicinal cannabis telehealth platforms (Alternaleaf, Polln, Tetra Health) can provide prescriptions and ongoing management independently.

Frequently asked questions — cannabis for women’s health

Is cannabis good for period pain? Observational evidence and clinical experience strongly support cannabis for period pain relief. Both CBD (anti-inflammatory, muscle-relaxant) and THC (visceral analgesic) contribute to relief. Many Australian women use cannabis as a first-line or adjunct period pain treatment.

Can cannabis help with menopause? Yes — cannabis is prescribed for menopausal sleep disruption, anxiety, mood disturbance and musculoskeletal pain. Evidence for hot flash reduction is early but promising. Discuss your specific symptoms with a prescriber to identify the right product approach.

Is CBD or THC better for women’s health conditions? It depends on the symptom. CBD is preferred for daytime anxiety, mood, and mild pain (particularly for women who cannot tolerate psychoactive effects). THC is more effective for sleep, severe pain and significant cramping. Many conditions benefit from both together — balanced products are often prescribed.

Can I use cannabis during my period? Yes — most women who use cannabis for dysmenorrhoea use it specifically during menstruation and the days leading up to it. Cyclic dosing (using cannabis only during symptomatic phases) is a common and clinically appropriate approach.

Will cannabis affect my fertility? Some preclinical evidence suggests heavy cannabis use may affect ovulation and reproductive hormones. At therapeutic medicinal doses, this risk is considered low. If you are actively trying to conceive, discuss timing and dosing with your prescriber. Cease cannabis use when pregnancy is confirmed.